Sonoma Pharmaceuticals, Inc.
Close on Oct 19, 2026
- Market cap
- $4.31M
- P/E (TTM)
- –
- Dividend yield
- –
About Sonoma Pharmaceuticals
Surgical & Medical Instruments & Apparatus, SIC 3841
Sonoma Pharmaceuticals, Inc. develops and manufactures stabilized hypochlorous acid products across six primary business channels: wound care, dermatology, eye care, podiatry, animal health care, and non-toxic surface disinfectants. Its offerings include prescription, over-the-counter, and office-dispense topical solutions, hydrogels, sprays, and cleansers designed to alleviate pain, itch, redness, and scarring while supporting skin and wound healing. The company distributes its medical device solutions directly and through commercial partners to hospitals, physicians, retail pharmacy chains, pet specialty stores, and everyday consumers.
The company operates internationally, commercializing products directly or through distribution partnerships across more than 55 countries worldwide, including the United States, Europe, Asia, and Latin America. All manufacturing activities take place at a dedicated production facility located in Zapopan, Mexico. Sonoma Pharmaceuticals maintains corporate headquarters in Boulder, Colorado, with additional operational entities based in the Netherlands.
Summary of the business section of Sonoma Pharmaceuticals's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Sonoma Pharmaceuticals, Inc.
- Founded
- 1999
- Headquarters
- Boulder, CO
- Address
- 5445 Conestoga Court, Suite 150 80301
- Phone
- (800) 759-9305
- Website
- sonomapharma.com
- Employees
- 250, Mar 31, 2026
- Industry
- Surgical & Medical Instruments & Apparatus
- Incorporated in
- Delaware
- Fiscal year ends
- March 31
- Auditor
- Frazier & Deeter, LLC, Nashville, Tennessee
Stock & identifiers
- Ticker
- SNOA
- Exchange
- Nasdaq
- IPO date
- Jan 26, 2007
- Shares outstanding
- 5M, Aug 6, 2026
- Public float
- $6.32M, Sep 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-20 reverse, Nov 7, 2024; 1-for-20 reverse, Aug 30, 2024; 1-for-9 reverse, Jun 20, 2019; 1-for-9 reverse, Jun 19, 2019; 1-for-5 reverse, Jun 30, 2016; 1-for-5 reverse, Jun 27, 2016; 1-for-7 reverse, Jun 25, 2013; 1-for-7 reverse, Apr 1, 2013
- SEC CIK
- 1367083
- CUSIP
- 83558L303
- ISIN
- US83558L3033
- LEI
- 54930008C5Z4F02SWO71
- EIN
- 68-0423298
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Poggetto John Dal | Controller | 15,000 |
| Amy Moss Trombly | Chief Executive Officer | 153,586 |
| Jerome J. Dvonch | Chief Financial Officer | 84,595 |
| Bruce Thornton | Executive VP and COO | 154,411 |
| Vanessa Jacoby | Director | – |
| John McLaughlin | Director | 48,728 |
| Philippe Weigerstorfer | Director | 22,500 |
| Jay E. Birnbaum | Director | 51,659 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2026 Amy Trombly | $741.12K | $641.73K | $411.16K | $11 | – |
| FY2025 Amy Trombly | $597.08K | $553.87K | $444.95K | $11 | – |
| FY2024 Amy Trombly | $726.54K | $697.36K | $483.06K | $17 | – |
| FY2023 Amy Trombly | $559.94K | $509.83K | $299.23K | $24 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“Additionally, we had approximately 250 employees in Mexico.”
Corporate history
Events identified from SEC filings